Hangzhou Bio‑Sincerity Poised for 2025 Surge as China Innovation‑Drug Reimbursement ExpandsExplore Hangzhou Bio‑Sincerity Pharma‑Tech’s oncology pipeline and how China’s new medical‑insurance policy could boost its 2025 upside.BIO-S AI generated 04/11/2025, 07:34 3 minutes to read
